NCT02581007View on ClinicalTrials.gov

Reduced Intensity Conditioning Transplant Using Haploidentical Donors

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 26, 2015

Primary Completion Date

November 5, 2019

Study Completion Date

December 28, 2020

Conditions
Chronic Myelogenous LeukemiaAcute Myelogenous LeukemiaMyelodysplastic SyndromeAcute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaHodgkin's LymphomaNon-Hodgkin's LymphomaMyelofibrosisCMMLMultiple Myeloma
Interventions
DRUG

Fludarabine

fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;

DRUG

Melphalan

DRUG

Cyclophosphamide

cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.

PROCEDURE

peripheral blood stem cell transplant

Trial Locations (1)

30342

Northside Hospital, Atlanta

All Listed Sponsors
collaborator

Blood and Marrow Transplant Group of Georgia

OTHER

lead

Northside Hospital, Inc.

OTHER

NCT02581007 - Reduced Intensity Conditioning Transplant Using Haploidentical Donors | Biotech Hunter | Biotech Hunter